liu.seSearch for publications in DiVA
Change search
Link to record
Permanent link

Direct link
Venetsanos, Dimitrios
Publications (9 of 9) Show all publications
Venetsanos, D., Omerovic, E., Sarno, G., Pagonis, C., Witt, N., Calais, F., . . . Alfredsson, J. (2021). Long term outcome after treatment of de novo coronary artery lesions using three different drug coated balloons. International Journal of Cardiology, 325, 30-36
Open this publication in new window or tab >>Long term outcome after treatment of de novo coronary artery lesions using three different drug coated balloons
Show others...
2021 (English)In: International Journal of Cardiology, ISSN 0167-5273, E-ISSN 1874-1754, Vol. 325, p. 30-36Article in journal (Refereed) Published
Abstract [en]

Objective: To evaluate the long-term efficacy of three currently available drug coated balloons (DCB) for the treat-ment of de-novo coronary lesions.

Methods: This was a retrospective analysis of prospectively collected data from the Swedish Coronary Angiogra-phy and Angioplasty Registry. Between 2009 and 2017, three currently available DCB brands used in the treat-ment of de novo lesions were included. Outcomes were clinically driven restenosis and target lesionthrombosis (TLT) (per device) and major adverse cardiac events (MACE) including death, myocardial infarctionor target vessel revascularization (per patient) at 4 years. Multivariable Cox regression models were used to ad-just for differences.

Results: We included 6715 lesions treated with DCBs, 4483 SeQuent® Please (S-DCB), 1071 IN.PACT Falcon (I-DCB) and 1161 Pantera® Lux (P-DCB), in 5670 patients. The mean DCB diameter was 2.4 mm. Bailout stentingoccurred in 6.7% of lesions. Angiographic success was 98.5%. The overall cumulative rate of restenosis was 5.5% (299 events). The risk for reported restenosis did not signifi-cantly differ between I-DCB vs S-DCB, adjusted hazard ratio (aHR) 0.96; 95% confidence interval (CI) 0.69–1.34,P-DCB vs S-DCB aHR 0.88; 95% CI 0.63–1.23 and I-DCB vs P-DCB aHR 1.10; 95% CI 0.72–1.68. The cumulative riskfor TLT was 0.8% in all three DCBs. The risk for MACE or individual components of MACE did not differ betweenthe three patient-groups.

Conclusion:In de novo coronary lesions, we found comparable long-term efficacy with three currently availableDCB brands. DCB angioplasty was feasible with low risk for long-term restenosis and TLT.

Place, publisher, year, edition, pages
Elsevier, 2021
Keywords
Drug-coated balloons; Drug-eluting balloons; Restenosis; de novo lesions
National Category
Cardiac and Cardiovascular Systems
Identifiers
urn:nbn:se:liu:diva-174350 (URN)10.1016/j.ijcard.2020.09.054 (DOI)000623745900005 ()32980433 (PubMedID)2-s2.0-85092016972 (Scopus ID)
Available from: 2021-03-20 Created: 2021-03-20 Last updated: 2022-05-25Bibliographically approved
Alfredsson, J., Omar, K., Csog, J., Venetsanos, D., Janzon, M. & Ekstedt, M. (2020). Bleeding complications with clopidogrel or ticagrelor in ST-elevation myocardial infarction patients: A real life cohort study of two treatment strategies. IJC Heart & Vasculature, 27, Article ID 100495.
Open this publication in new window or tab >>Bleeding complications with clopidogrel or ticagrelor in ST-elevation myocardial infarction patients: A real life cohort study of two treatment strategies
Show others...
2020 (English)In: IJC Heart & Vasculature, E-ISSN 2352-9067, Vol. 27, article id 100495Article in journal (Refereed) Published
Abstract [en]

Introduction

Dual antiplatelet therapy (DAPT), including potent P2Y12 inhibition after ST-elevation myocardial infarction (STEMI) is recommended in clinical guidelines. However, bleeding complications are common, and associated with worse outcomes. The aim of this study was to assess incidence of bleeding events with a clopidogrel-based compared to a ticagrelor-based DAPT strategy, in a real world population. Secondary aims were to assess ischemic complications and mortality.

Methods and Results

We identified 330 consecutive STEMI patients with a clopidogrel-based and 330 with a ticagrelor-based DAPT strategy. Patientś medical records were searched for bleeding and ischemic complications, over 6 months follow-up.

The two groups were well balanced in baseline characteristics, age (69 years inboth groups), sex (31% vs 32% females), history of diabetes (19% vs 21%), hypertension (43% in both) and MI (17% vs 15%). There was no difference in CRUSADE bleeding score (28 vs 29). After discharge, there were more than twice as many bleeding events with a ticagrelor-based compared with a clopidogrel-based strategy (13.3% vs. 6.5%, p = 0.005). Bleeding events included significantly more severe bleeding complications (TIMI major/minor [5.8 vs 1.0, p = 0.001]) during the ticagrelor-based period. There was no significant difference in the composite of death, MI or stroke (7.8% vs 7.1%, p = 0.76).

Conclusions

In this observational study, a ticagrelor-based DAPT strategy was associated with significantly more bleeding complications, without any significant change in death, MI or stroke. Larger studies are needed to determine whether bleeding complications off-sets benefits with a more potent DAPT strategy in older and more comorbid real-life patients.

Place, publisher, year, edition, pages
Elsevier, 2020
Keywords
Myocardial infarction; Ticagrelor; Clopidogrel; Bleeding complications
National Category
Cell and Molecular Biology
Identifiers
urn:nbn:se:liu:diva-174000 (URN)10.1016/j.ijcha.2020.100495 (DOI)000524982300010 ()32309533 (PubMedID)2-s2.0-85081916635 (Scopus ID)
Note

Funding Agencies|County Council of Ostergotland; ALF grants Region Ostergotland

Available from: 2021-03-16 Created: 2021-03-16 Last updated: 2022-02-10Bibliographically approved
Venetsanos, D., Sederholm Lawesson, S., Fröbert, O., Omerovic, E., Henareh, L., Robertsson, L., . . . Swahn, E. (2019). Sex-related response to bivalirudin and unfractionated heparin in patients with acute myocardial infarction undergoing percutaneous coronary intervention: A subgroup analysis of the VALIDATE-SWEDEHEART trial. European Heart Journal: Acute Cardiovascular Care, 8(6), 502-509
Open this publication in new window or tab >>Sex-related response to bivalirudin and unfractionated heparin in patients with acute myocardial infarction undergoing percutaneous coronary intervention: A subgroup analysis of the VALIDATE-SWEDEHEART trial
Show others...
2019 (English)In: European Heart Journal: Acute Cardiovascular Care, ISSN 2048-8726, E-ISSN 2048-8734, Vol. 8, no 6, p. 502-509Article in journal (Refereed) Published
Abstract [en]

Aims:

Our aim was to study the impact of sex on anticoagulant treatment outcomes during percutaneous coronary intervention in acute myocardial infarction patients.

Methods:

This study was a prespecified analysis of the Bivalirudin versus Heparin in ST-Segment and Non ST-Segment Elevation Myocardial Infarction in Patients on Modern Antiplatelet Therapy in the Swedish Web System for Enhancement and Development of Evidence-based Care in Heart Disease Evaluated according to Recommended Therapies Registry Trial (VALIDATE-SWEDEHEART) trial, in which patients with myocardial infarction were randomised to bivalirudin or unfractionated heparin during percutaneous coronary intervention. The primary outcome was the composite of death, myocardial infarction or major bleeding at 180 days.

Results:

There was a lower risk of the primary outcome in women assigned to bivalirudin than to unfractionated heparin (13.6% vs 17.1%, hazard ratio 0.78, 95% confidence interval (0.60–1.00)) with no significant difference in men (11.8% vs 11.2%, hazard ratio 1.06 (0.89–1.26), p for interaction 0.05). The observed difference was primarily due to lower risk of major bleeding (Bleeding Academic Research Consortium definition 2, 3 or 5) associated with bivalirudin in women (8.9% vs 11.8%, hazard ratio 0.74 (0.54–1.01)) but not in men (8.5% vs 7.3%, hazard ratio 1.16 (0.94–1.43) in men, pfor interaction 0.02). Conversely, no significant difference in the risk of Bleeding Academic Research Consortium 3 or 5 bleeding, associated with bivalirudin, was found in women 4.5% vs 5.4% (hazard ratio 0.84 (0.54–1.31)) or men 2.9% vs 2.1% (hazard ratio 1.36 (0.93–1.99)). Bleeding Academic Research Consortium 2 bleeding occurred significantly less often in women assigned to bivalirudin than to unfractionated heparin. The risk of death or myocardial infarction did not significantly differ between randomised treatments in men or women.

Conclusion:

In women, bivalirudin was associated with a lower risk of adverse outcomes, compared to unfractionated heparin, primarily due to a significant reduction in Bleeding Academic Research Consortium 2 bleeds.

Place, publisher, year, edition, pages
Sage Publications, 2019
Keywords
Gendersex; bivalirudin; heparin, myocardial infarction; percutaneous coronary intervention
National Category
Cardiac and Cardiovascular Systems
Identifiers
urn:nbn:se:liu:diva-155803 (URN)10.1177/2048872618803760 (DOI)000484942800003 ()30351167 (PubMedID)
Note

Funding agencies: Swedish Heart-Lung FoundationSwedish Heart-Lung Foundation; Swedish Research CouncilSwedish Research Council; AstraZenecaAstraZeneca; the Medicines Company; Swedish Foundation for Strategic Research (as part of the Tailoring of treatment in all comers wit

Available from: 2019-03-28 Created: 2019-03-28 Last updated: 2023-08-28Bibliographically approved
Erlinge, D., Koul, S., Omerovic, E., Fröbert, O., Linder, R., Danielewicz, M., . . . James, S. (2018). Bivalirudin versus heparin monotherapy in non-ST-segment elevation myocardial infarction.. European Heart Journal: Acute Cardiovascular Care
Open this publication in new window or tab >>Bivalirudin versus heparin monotherapy in non-ST-segment elevation myocardial infarction.
Show others...
2018 (English)In: European Heart Journal: Acute Cardiovascular Care, ISSN 2048-8726, E-ISSN 2048-8734Article in journal (Refereed) Epub ahead of print
Abstract [en]

Background: The optimal anti-coagulation strategy for patients with non-ST-elevation myocardial infarction treated with percutaneous coronary intervention is unclear in contemporary clinical practice of radial access and potent P2Y12-inhibitors. The aim of this study was to investigate whether bivalirudin was superior to heparin monotherapy in patients with non-ST-elevation myocardial infarction without routine glycoprotein IIb/IIIa inhibitor use.less thanbr /greater thanMethods: In a large pre-specified subgroup of the multicentre, prospective, randomised, registry-based, open-label clinical VALIDATE-SWEDEHEART trial we randomised patients with non-ST-elevation myocardial infarction undergoing percutaneous coronary intervention, treated with ticagrelor or prasugrel, to bivalirudin or heparin monotherapy with no planned use of glycoprotein IIb/IIIa inhibitors during percutaneous coronary intervention. The primary endpoint was the rate of a composite of all-cause death, myocardial infarction or major bleeding within 180 days.less thanbr /greater thanResults: A total of 3001 patients with non-ST-elevation myocardial infarction, were enrolled. The primary endpoint occurred in 12.1% (182 of 1503) and 12.5% (187 of 1498) of patients in the bivalirudin and heparin groups, respectively (hazard ratio of bivalirudin compared to heparin treatment 0.96, 95% confidence interval 0.78-1.18, p=0.69). The results were consistent in all major subgroups. All-cause death occurred in 2.0% versus 1.7% (hazard ratio 1.15, 0.68-1.94, p=0.61), myocardial infarction in 2.3% versus 2.5% (hazard ratio 0.91, 0.58-1.45, p=0.70), major bleeding in 8.9% versus 9.1% (hazard ratio 0.97, 0.77-1.24, p=0.82) and definite stent thrombosis in 0.3% versus 0.2% (hazard ratio 1.33, 0.30-5.93, p=0.82).less thanbr /greater thanConclusion: Bivalirudin as compared to heparin during percutaneous coronary intervention for non-ST-elevation myocardial infarction did not reduce the composite of all-cause death, myocardial infarction or major bleeding in non-ST-elevation myocardial infarction patients receiving current recommended treatments with modern P2Y12-inhibitors and predominantly radial access.

Place, publisher, year, edition, pages
Sage Publications, 2018
Keywords
Bivalirudin; heparin; non-ST-elevation myocardial infarction
National Category
Cardiac and Cardiovascular Systems
Identifiers
urn:nbn:se:liu:diva-155804 (URN)10.1177/2048872618805663 (DOI)30281320 (PubMedID)
Funder
Swedish Heart Lung FoundationSwedish Research CouncilSwedish Foundation for Strategic Research
Available from: 2019-03-28 Created: 2019-03-28 Last updated: 2023-08-28
Venetsanos, D., Sederholm Lawesson, S., James, S., Koul, S., Erlinge, D., Swahn, E. & Alfredsson, J. (2018). Bivalirudin versus heparin with primary percutaneous coronary intervention. American Heart Journal, 201, 9-16
Open this publication in new window or tab >>Bivalirudin versus heparin with primary percutaneous coronary intervention
Show others...
2018 (English)In: American Heart Journal, ISSN 0002-8703, E-ISSN 1097-6744, Vol. 201, p. 9-16Article in journal (Refereed) Published
Abstract [en]

Background: Optimal adjunctive therapy in ST-segment elevation myocardial infarction (STEMI) patients treated with primary PCI (PPCI) remains a matter of debate. Our aim was to compare the efficacy and safety of bivalirudin to unfractionated heparin (UFH), with or without glycoprotein IIb/IIIa inhibitors (GPI) in a large real-world population, using data from the Swedish national registry, SWEDEHEART. Method: From 2008 to 2014 we identified 23,800 STEMI patients presenting within 12 hours from symptom onset treated with PPCI and UFH +/- GPI or bivalirudin +/- GPI. Primary outcomes included 30-day all-cause mortality and major in-hospital bleeding. Multivariable regression models and propensity score modelling were utilized to study adjusted association between treatment and outcome. Results: Treatment with UFH +/- GPI was associated with similar risk of 30-day mortality compared to bivalirudin +/- GPI (5.3% vs 5.5%, adjusted HR 0.94; 95% CI 0.82-1.07). The adjusted risk for 1-year mortality, 30-day and 1-year stent thrombosis and re-infarction did not differ significantly between UFH +/- GPI and bivalirudin +/- GPI. In contrast, treatment with UFH +/- GPI was associated with a significant higher risk of major in-hospital bleeding (adjusted OR 1.62; 95% CI 1.30-2.03). When including GPI use in the multivariable analysis, the difference was attenuated and no longer significant (adjusted OR 1.25; 95% CI 0.92-1.70). Conclusion: Bivalirudin +/- GPI was associated with significantly lower risk for major in hospital bleeding but no significant difference in 30-day or one year mortality, stent thrombosis or re-infarction compared with UFH +/- GPI. The bleeding reduction associated with bivalirudin could be explained by the greater GPI use with UFH. (C) 2018 Elsevier Inc. All rights reserved.

Place, publisher, year, edition, pages
Philadelphia, United States: Mosby, Inc., 2018
National Category
Cardiac and Cardiovascular Systems
Identifiers
urn:nbn:se:liu:diva-149694 (URN)10.1016/j.ahj.2018.03.014 (DOI)000436562100002 ()29910059 (PubMedID)2-s2.0-85046083385 (Scopus ID)
Note

Funding Agencies|ALF Grants, Region Ostergotland

Available from: 2018-07-18 Created: 2018-07-18 Last updated: 2019-05-01Bibliographically approved
Venetsanos, D., Sederholm Lawesson, S., Panayi, G., Todt, T., Berglund, U., Swahn, E. & Alfredsson, J. (2018). Long-term efficacy of drug coated balloons compared with new generation drug-eluting stents for the treatment of de novo coronary artery lesions. Catheterization and cardiovascular interventions, 92(5), E317-E326
Open this publication in new window or tab >>Long-term efficacy of drug coated balloons compared with new generation drug-eluting stents for the treatment of de novo coronary artery lesions
Show others...
2018 (English)In: Catheterization and cardiovascular interventions, ISSN 1522-1946, E-ISSN 1522-726X, Vol. 92, no 5, p. E317-E326Article in journal (Refereed) Published
Abstract [en]

Background Studies comparing drug coated balloons (DCB) with new generation drug-eluting stents (nDES) for the treatment of de novo coronary artery lesions are lacking. Methods From 2009 to 2016, DCB or nDES used for treatment of de novo coronary lesions at our institution were included, in total 1,197 DEB and 6,458 nDES. We evaluated target lesions restenosis (TLR) and definite target lesion thrombosis (TLT). Propensity score modeling were utilized to study adjusted associations between treatment and outcomes. Results Median follow-up was 901days. DCB patients were older, with higher cardiovascular risk profile. Bailout stenting after DCB was performed in 8% of lesions. The cumulative rate of TLR and TLT was 7.0 vs. 4.9% and 0.2 vs. 0.8% for DCB vs. nDES, respectively. Before adjustment, DCB was associated with a higher risk of TLR [hazard ratio (HR) 1.44; 95% confidence interval (CI) 1.07-1.94] and a non-significantly lower risk of TLT (HR 0.30; 95% CI 0.07-1.24), compared to nDES. In the propensity matched population consisted of 1,197 DCB and 1,197 nDES, treatment with DCB was associated with similar risk for TLR (adjusted HR 1.05; 95% CI 0.72-1.53) but significantly lower risk for TLT (adjusted HR 0.18; 95% CI 0.04-0.82) compared to nDES. Conclusions Treatment with DCB was associated with a similar risk of TLR and a lower risk of definite TLT compared with nDES. In selected cases, DCB appears as a good alternative to nDES for the treatment of de novo coronary lesions.

Place, publisher, year, edition, pages
WILEY, 2018
Keywords
de novo lesions; drug-coated balloon; drug-eluting balloon; restenosis; stent thrombosis
National Category
Cardiac and Cardiovascular Systems
Identifiers
urn:nbn:se:liu:diva-153177 (URN)10.1002/ccd.27548 (DOI)000450359400003 ()29481718 (PubMedID)
Note

Funding Agencies|This research received no specific grant from any funding agency in the public commercial or not-for-profit sectors.

Available from: 2018-12-03 Created: 2018-12-03 Last updated: 2019-05-01
Koul, S., Smith, J. G., Gotberg, M., Omerovic, E., Alfredsson, J., Venetsanos, D., . . . Erlinge, D. (2018). No Benefit of Ticagrelor Pretreatment Compared With Treatment During Percutaneous Coronary Intervention in Patients With ST-Segment-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. Circulation. Cardiovascular Interventions, 11(3), Article ID e005528.
Open this publication in new window or tab >>No Benefit of Ticagrelor Pretreatment Compared With Treatment During Percutaneous Coronary Intervention in Patients With ST-Segment-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention
Show others...
2018 (English)In: Circulation. Cardiovascular Interventions, ISSN 1941-7640, E-ISSN 1941-7632, Vol. 11, no 3, article id e005528Article in journal (Refereed) Published
Abstract [en]

Background-The effects of ticagrelor pretreatment in patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention (PCI) is debated. This study investigated the effects of ticagrelor pretreatment on clinical outcomes in this patient group. Methods and Results-Patients with ST-segment-elevation myocardial infarction undergoing primary PCI were included from October 2010 to October 2014 in Sweden. Screening was done using the SWEDEHEART register (Swedish Web-System for Enhancement and Development of Evidence-Based Care in Heart Disease Evaluated According to Recommended Therapies). A total of 7433 patients were included for analysis with 5438 patients receiving ticagrelor pretreatment and 1995 patients with ticagrelor given only in the catheterization laboratory. The primary end point of the study was 30-day event rates of a composite of all-cause mortality, myocardial infarction (MI), and stent thrombosis. Secondary end points were mortality, MI, or stent thrombosis alone and major in-hospital bleeding. Crude event rates showed no difference in 30-day composite end point (6.2% versus 6.5%; P=0.69), mortality (4.5% versus 4.7%; P=0.86), MI (1.6% versus 1.7%; P=0.72), or stent thrombosis (0.5% versus 0.4%; P=0.80) with ticagrelor pretreatment. Three different statistical models were used to correct for baseline differences. No difference in the composite end point, mortality, MI, or stent thrombosis was seen between the 2 groups after statistical adjustment. No increase in in-hospital major bleeding rate was observed with ticagrelor pretreatment. Conclusions-Ticagrelor pretreatment versus ticagrelor given in the catheterization laboratory in patients with ST-segment-elevation myocardial infarction undergoing primary PCI did not improve the composite end point of all-cause mortality or MI or stent thrombosis or its individual components at 30 days.

Place, publisher, year, edition, pages
LIPPINCOTT WILLIAMS & WILKINS, 2018
Keywords
myocardial infarction; percutaneous coronary intervention; ST-elevation myocardial infarction; stents; thrombosis
National Category
Cardiac and Cardiovascular Systems
Identifiers
urn:nbn:se:liu:diva-149749 (URN)10.1161/CIRCINTERVENTIONS.117.005528 (DOI)000435566100002 ()29870381 (PubMedID)
Note

Funding Agencies|Swedish Heart-Lung Foundation; TOTAL-AMI

Available from: 2018-07-24 Created: 2018-07-24 Last updated: 2019-05-01
Venetsanos, D., Lindahl, T., Sederholm Lawesson, S., Gustafsson, K., Wallen, H., Erlinge, D., . . . Alfredsson, J. (2018). Pretreatment with ticagrelor may offset additional inhibition of platelet and coagulation activation with bivalirudin compared to heparin during primary percutaneous coronary intervention. Thrombosis Research, 171, 38-44
Open this publication in new window or tab >>Pretreatment with ticagrelor may offset additional inhibition of platelet and coagulation activation with bivalirudin compared to heparin during primary percutaneous coronary intervention
Show others...
2018 (English)In: Thrombosis Research, ISSN 0049-3848, E-ISSN 1879-2472, Vol. 171, p. 38-44Article in journal (Refereed) Published
Abstract [en]

Background

It remains unknown if bivalirudin compared to heparin confers any additional inhibition of platelet and coagulation activation during primary percutaneous coronary intervention(PPCI) after pretreatment with ticagrelor.

Methods

In this substudy of VALIDATE-SWEDEHEART trial, 103 patients pretreated with ticagrelor were randomized before PPCI to heparin or bivalirudin. Blood samples were collected before and 1 and 12 h after PPCI. We measured platelet reactivity (PR) using Multiplate, soluble P-selectin, thrombin-antithrombin complexes (TAT) and prothrombin fragments 1 + 2 (F1 + 2) as markers of platelet and coagulation activation.

Results

The median (IQR) time from ticagrelor administration to randomization was 63 (29) vs 60 (24) minutes, p = 0.28. ADP-induced PR did not significantly differ between groups over time (heparin vs bivalirudin, AUC 73 (62) vs 74 (68), p = 0.74, 32 (42) vs 43 (51), p = 0.38, 15 (15) vs 19 (15), p = 0.29, before, 1 and 12 h after PPCI). Soluble P-selectin did not significantly differ between groups. At 1 h TAT significantly increased with bivalirudin (3.0 (1.3) to 4.3 (4.2) ug/L; p < 0.01), but not with UFH (3.1 (2.1) to 3.5 (1.6) ug/L, p = 0.24). F1 + 2 increased in both groups but the rise was numerically higher with bivalirudin (170 (85) to 213 (126) pmol/L vs 168 (118) to 191 (103) pmol/L). At 12 h, a comparable significant increase in thrombin generation was observed in both groups.

Conclusion

In patients treated with ticagrelor, we found no major differences between bivalirudin and heparin in platelet aggregation or coagulation markers, which is in agreement with the neutral clinical results of the VALIDATE-SWEDEHEART study.

Place, publisher, year, edition, pages
Pergamon Press, 2018
Keywords
Bivalirudin; Heparin; Coagulation; Platelet; Aggregation; Thrombin
National Category
Cardiac and Cardiovascular Systems
Identifiers
urn:nbn:se:liu:diva-153386 (URN)10.1016/j.thromres.2018.09.046 (DOI)000450362200006 ()30248659 (PubMedID)2-s2.0-85053795837 (Scopus ID)
Note

Funding Agencies|AstraZeneca

Available from: 2018-12-13 Created: 2018-12-13 Last updated: 2019-05-02Bibliographically approved
Andell, P., Berntorp, K., Christiansen, E. H., Gudmundsdottir, I. J., Sandhall, L., Venetsanos, D., . . . Gotberg, M. (2018). Reclassification of Treatment Strategy With Instantaneous Wave-Free Ratio and Fractional Flow Reserve A Substudy From the iFR-SWEDEHEART Trial. JACC: Cardiovascular Interventions, 11(20), 2084-2094
Open this publication in new window or tab >>Reclassification of Treatment Strategy With Instantaneous Wave-Free Ratio and Fractional Flow Reserve A Substudy From the iFR-SWEDEHEART Trial
Show others...
2018 (English)In: JACC: Cardiovascular Interventions, ISSN 1936-8798, E-ISSN 1876-7605, Vol. 11, no 20, p. 2084-2094Article in journal (Refereed) Published
Abstract [en]

OBJECTIVES The authors sought to compare reclassification of treatment strategy following instantaneous wave-free ratio (iFR) and fractional flow reserve (FFR). BACKGROUND iFR was noninferior to FFR in 2 large randomized controlled trials in guiding coronary revascularization. Reclassification of treatment strategy by FFR is well-studied, but similar reports on iFR are lacking. METHODS The iFR-SWEDEHEART (Instantaneous Wave-Free Ratio Versus Fractional Flow Reserve in Patients With Stable Angina Pectoris or Acute Coronary Syndrome Trial) study randomized 2,037 participants with stable angina or acute coronary syndrome to treatment guided by iFR or FFR. Interventionalists entered the preferred treatment (optimal medical therapy [OMT], percutaneous coronary intervention [PCI], or coronary artery bypass grafting [CABG]) on the basis of coronary angiograms, and the final treatment decision was mandated by the iFR/FFR measurements. RESULTS In the iFR/FFR (n = 1,009/n = 1,004) populations, angiogram-based treatment approaches were similar (p = 0.50) with respect to OMT (38%/35%), PCI of 1 (37%/39%), 2 (15%/16%), and 3 vessels (2%/2%) and CABG (8%/8%). iFR and FFR reclassified 40% and 41% of patients, respectively (p = 0.78). The majority of reclassifications were conversion of PCI to OMT in both the iFR/FFR groups (31.4%/29.0%). Reclassification increased with increasing number of lesions evaluated (odds ratio per evaluated lesion for FFR: 1.46 [95% confidence interval: 1.22 to 1.76] vs. iFR 1.37 [95% confidence interval: 1.18 to 1.59]). Reclassification rates for patients with 1, 2, and 3 assessed vessels were 36%, 52%, and 53% (p amp;lt; 0.01). CONCLUSIONS Reclassification of treatment strategy of intermediate lesions was common and occurred in 40% of patients with iFR or FFR. The most frequent reclassification was conversion from PCI to OMT regardless of physiology modality. Irrespective of the physiological index reclassification of angiogram-based treatment strategy increased with the number of lesions evaluated. (c) 2018 by the American College of Cardiology Foundation.

Place, publisher, year, edition, pages
ELSEVIER SCIENCE INC, 2018
Keywords
coronary artery bypass grafting; coronary artery disease; coronary physiology; FFR; iFR; percutaneous coronary intervention
National Category
Cardiac and Cardiovascular Systems
Identifiers
urn:nbn:se:liu:diva-152375 (URN)10.1016/j.jcin.2018.07.035 (DOI)000447436200013 ()30336812 (PubMedID)
Available from: 2018-11-05 Created: 2018-11-05 Last updated: 2019-05-01
Organisations

Search in DiVA

Show all publications